Clinical trial NCT00139698: Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Official title: A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Essential Hypertension
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-08-31
Enrollment: 410
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension


Eligibility criteria: Inclusion Criteria:

* Subject has mild to moderate hypertension

Exclusion Criteria:

* History of secondary hypertension

Primary outcomes:
measure: Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Secondary outcomes:
measure: Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Other outcomes:
Locations:
city: Medellin
country: Colombia
facility: Pfizer Investigational Site
state: Antioquia
city: Barranquilla
country: Colombia
facility: Pfizer Investigational Site
state: Atlantico
city: Cartagena
country: Colombia
facility: Pfizer Investigational Site
state: Atlantico
city: Bogota
country: Colombia
facility: Pfizer Investigational Site
state: Cundinamarca
city: Cali
country: Colombia
facility: Pfizer Investigational Site
state: Valle Del Cauca
city: Escobedo
country: Ecuador
facility: Pfizer Investigational Site
state: Guayas
city: Quito
country: Ecuador
facility: Pfizer Investigational Site
state: Pichincha
city: NT
country: Hong Kong
facility: Pfizer Investigational Site
city: Shatin, NT
country: Hong Kong
facility: Pfizer Investigational Site
city: Jakarta
country: Indonesia
facility: Pfizer Investigational Site
city: Jakarta
country: Indonesia
facility: Pfizer Investigational Site
city: Jakarta
country: Indonesia
facility: Pfizer Investigational Site
city: Surabaya
country: Indonesia
facility: Pfizer Investigational Site
city: Seremban
country: Malaysia
facility: Pfizer Investigational Site
state: Negeri Sembilan
city: Kuching
country: Malaysia
facility: Pfizer Investigational Site
state: Sarawak
city: San Juan
country: Philippines
facility: Pfizer Investigational Site
state: Metro Manila
city: Quezon
country: Philippines
facility: Pfizer Investigational Site
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
city: Guei-Shan Shiang
country: Taiwan
facility: Pfizer Investigational Site
state: Tau-Yuan Shian
city: Kaohsiung
country: Taiwan
facility: Pfizer Investigational Site
city: Taipei
country: Taiwan
facility: Pfizer Investigational Site
city: Taipei
country: Taiwan
facility: Pfizer Investigational Site
city: Khet Rajathevee
country: Thailand
facility: Pfizer Investigational Site
state: Bangkok
city: Bangkok
country: Thailand
facility: Pfizer Investigational Site
city: Bangkok
country: Thailand
facility: Pfizer Investigational Site
city: Chiang Mai
country: Thailand
facility: Pfizer Investigational Site
city: Bornova/Izmir
country: Turkey
facility: Pfizer Investigational Site
city: Haseki/Istanbul
country: Turkey
facility: Pfizer Investigational Site
city: Sihhiye/Ankara
country: Turkey
facility: Pfizer Investigational Site
city: SÂ¿hhiye/Ankara
country: Turkey
facility: Pfizer Investigational Site
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: